Traders should monitor upcoming quarterly reports for TONMYA's commercial uptake and revenue contribution. While the publication strengthens scientific credibility, it does not signal immediate financial upside. Consider this supportive of long-term positioning, not a near-term catalyst.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced the publication of a peer-reviewed pharmacokinetic study supporting the FDA-approved TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, reinforcing its mechanism and safety profile. The drug, launched in November 2025, is the first new FDA-approved treatment for fibromyalgia in over 15 years.
Key Facts
- TONMYA was approved by the FDA on August 15, 2025, for the treatment of fibromyalgia in adults.
- It is the first new prescription medicine approved for fibromyalgia in more than 15 years.
- The published study confirms TONMYA’s steady-state pharmacokinetic profile supports once-daily bedtime dosing with rapid absorption and bypass of first-pass metabolism.
- TONMYA has U.S. market exclusivity expected until 2034/2035 due to issued patents.
- No financial figures (revenue, earnings, guidance) were disclosed in the release.
Financial Impact
No material financial impact disclosed; publication supports commercial rationale but does not indicate sales performance.
Risk Factors
- Commercial execution risk: No data provided on actual sales or market adoption of TONMYA.
- Regulatory and reimbursement risk: Despite approval, payer coverage and prescribing rates remain uncertain.
- Clinical limitations: No efficacy data from Phase 3 trials included; safety and tolerability may limit use due to oral mucosal side effects.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274294 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers